Pharmerica (PMC) Tops Q1 EPS by 2c; Reaffirms

Pharmerica (NYSE: PMC) reported Q1 EPS of $0.42, $0.02 better than the analyst estimate of $0.40. Revenue for the quarter came in at $566.8 million versus the consensus estimate of $536.89 million.

PharMerica reaffirms its full year 2017 guidance metrics:

• Revenue in the range of $2.3 billion to $2.4 billion;
• Adjusted EBITDA in the range of $132.0 million to $142.0 million; and
• Adjusted diluted earnings per share in the range of $1.75 to $1.95.

For earnings history and earnings-related data on Pharmerica (PMC) click here.

You May Also Be Interested In

• Toll Brothers (TOL) Tops Q3 EPS by 5c, reaffirms guidance
• VNET Group (VNET) Misses Q2 EPS by 164c
• Klarna Group plc (KLAR) Tops Q2 EPS by 6c, Beats on Revenue; Offers FY26 Revenue Guidance